Antisense Technology for Cancer Therapy
Author Information
Author(s): G. Carter, N.R. Lemoine
Primary Institution: ICRF Oncology Group, Royal Postgraduate Medical School, Hammersmith Hospital
Hypothesis
Can antisense technology effectively target oncogenes and intracellular signaling pathways for cancer therapy?
Conclusion
Antisense technology shows promise in selectively inhibiting gene expression in cancer cells, but significant challenges remain before it can be widely applied in clinical settings.
Supporting Evidence
- Antisense agents can specifically inhibit the expression of oncogenes like c-myc and c-fos.
- Encouraging results have been achieved with antisense approaches in viral diseases like HIV.
- Antisense technology has potential applications in targeting specific mutations in cancer cells.
Takeaway
Scientists are exploring a new way to fight cancer by using special molecules that can turn off the bad genes that make cancer cells grow.
Methodology
This review discusses various strategies and experimental approaches in antisense technology for cancer therapy.
Potential Biases
Potential risks include non-specific targeting leading to unintended effects on normal cells.
Limitations
The review highlights that many human tumors arise from loss of gene expression, which complicates the application of antisense strategies.
Want to read the original?
Access the complete publication on the publisher's website